Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Feb;40(2):373–379. doi: 10.1128/aac.40.2.373

Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins.

C P Kelly 1, C Pothoulakis 1, F Vavva 1, I Castagliuolo 1, E F Bostwick 1, J C O'Keane 1, S Keates 1, J T LaMont 1
PMCID: PMC163119  PMID: 8834883

Abstract

Clostridium difficile diarrhea and colitis result from the actions of bacterial exotoxins on the colonic mucosa. This study examined the ability of hyperimmune bovine colostral antibodies to neutralize the biological effects of these toxins. Anti-C. difficile bovine immunoglobulin concentrate was prepared from the colostral milk of Holstein cows previously immunized with C. difficile toxoids. The anti-C. difficile bovine immunoglobulin concentrate contained high levels of bovine immunoglobulin G specific for C. difficile toxins A and B, as evaluated by enzyme-linked immunosorbent assay. Anti-C. difficile bovine immunoglobulin concentrate neutralized the cytotoxic effects of purified toxin A and toxin B on cultured human fibroblasts, whereas control bovine immunoglobulin concentrate had little toxin-neutralizing activity. Anti-C. difficile bovine immunoglobulin concentrate also blocked the binding of toxin A to its enterocyte receptor and inhibited the enterotoxic effects of C. difficile toxins on the rat ileum, as measured by an increased rat ileal loop weight/length ratio (63% inhibition; P < 0.01), increased mannitol permeability (92% inhibition; P < 0.01), and histologic grading of enteritis (P < 0.01 versus nonimmune bovine immunoglobulin concentrate). Thus, anti-C. difficile bovine immunoglobulin concentrate neutralizes the cytotoxic effects of C. difficile toxins in vitro and inhibits their enterotoxic effects in vivo. This agent may be clinically useful in the prevention and treatment of C. difficile diarrhea and colitis.

Full Text

The Full Text of this article is available as a PDF (925.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aronsson B., Granström M., Möllby R., Nord C. E. Enzyme-linked immunosorbent assay (ELISA) for antibodies to Clostridium difficile toxins in patients with pseudomembranous colitis and antibiotic-associated diarrhoea. J Immunol Methods. 1983 Jun 10;60(3):341–350. doi: 10.1016/0022-1759(83)90291-0. [DOI] [PubMed] [Google Scholar]
  2. Aronsson B., Granström M., Möllby R., Nord C. E. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection. 1985 May-Jun;13(3):97–101. doi: 10.1007/BF01642866. [DOI] [PubMed] [Google Scholar]
  3. Brunser O., Espinoza J., Figueroa G., Araya M., Spencer E., Hilpert H., Link-Amster H., Brüssow H. Field trial of an infant formula containing anti-rotavirus and anti-Escherichia coli milk antibodies from hyperimmunized cows. J Pediatr Gastroenterol Nutr. 1992 Jul;15(1):63–72. doi: 10.1097/00005176-199207000-00010. [DOI] [PubMed] [Google Scholar]
  4. Davidson G. P., Whyte P. B., Daniels E., Franklin K., Nunan H., McCloud P. I., Moore A. G., Moore D. J. Passive immunisation of children with bovine colostrum containing antibodies to human rotavirus. Lancet. 1989 Sep 23;2(8665):709–712. doi: 10.1016/s0140-6736(89)90771-x. [DOI] [PubMed] [Google Scholar]
  5. Dove C. H., Wang S. Z., Price S. B., Phelps C. J., Lyerly D. M., Wilkins T. D., Johnson J. L. Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun. 1990 Feb;58(2):480–488. doi: 10.1128/iai.58.2.480-488.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. FAHEY J. L., MCKELVEY E. M. QUANTITATIVE DETERMINATION OF SERUM IMMUNOGLOBULINS IN ANTIBODY-AGAR PLATES. J Immunol. 1965 Jan;94:84–90. [PubMed] [Google Scholar]
  7. Hilpert H., Brüssow H., Mietens C., Sidoti J., Lerner L., Werchau H. Use of bovine milk concentrate containing antibody to rotavirus to treat rotavirus gastroenteritis in infants. J Infect Dis. 1987 Jul;156(1):158–166. doi: 10.1093/infdis/156.1.158. [DOI] [PubMed] [Google Scholar]
  8. Johnson S., Gerding D. N., Janoff E. N. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J Infect Dis. 1992 Dec;166(6):1287–1294. doi: 10.1093/infdis/166.6.1287. [DOI] [PubMed] [Google Scholar]
  9. Kelly C. P., Becker S., Linevsky J. K., Joshi M. A., O'Keane J. C., Dickey B. F., LaMont J. T., Pothoulakis C. Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest. 1994 Mar;93(3):1257–1265. doi: 10.1172/JCI117080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kelly C. P., Pothoulakis C., LaMont J. T. Clostridium difficile colitis. N Engl J Med. 1994 Jan 27;330(4):257–262. doi: 10.1056/NEJM199401273300406. [DOI] [PubMed] [Google Scholar]
  11. Kelly C. P., Pothoulakis C., Orellana J., LaMont J. T. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology. 1992 Jan;102(1):35–40. doi: 10.1016/0016-5085(92)91781-x. [DOI] [PubMed] [Google Scholar]
  12. Kim K., Pickering L. K., DuPont H. L., Sullivan N., Wilkins T. In vitro and in vivo neutralizing activity of human colostrum and milk against purified toxins A and B of Clostridium difficile. J Infect Dis. 1984 Jul;150(1):57–62. doi: 10.1093/infdis/150.1.57. [DOI] [PubMed] [Google Scholar]
  13. Kim P. H., Iaconis J. P., Rolfe R. D. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun. 1987 Dec;55(12):2984–2992. doi: 10.1128/iai.55.12.2984-2992.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Leung D. Y., Kelly C. P., Boguniewicz M., Pothoulakis C., LaMont J. T., Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr. 1991 Apr;118(4 Pt 1):633–637. doi: 10.1016/s0022-3476(05)83393-1. [DOI] [PubMed] [Google Scholar]
  15. Libby J. M., Jortner B. S., Wilkins T. D. Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect Immun. 1982 May;36(2):822–829. doi: 10.1128/iai.36.2.822-829.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lyerly D. M., Bostwick E. F., Binion S. B., Wilkins T. D. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun. 1991 Jun;59(6):2215–2218. doi: 10.1128/iai.59.6.2215-2218.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lyerly D. M., Krivan H. C., Wilkins T. D. Clostridium difficile: its disease and toxins. Clin Microbiol Rev. 1988 Jan;1(1):1–18. doi: 10.1128/cmr.1.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lyerly D. M., Lockwood D. E., Richardson S. H., Wilkins T. D. Biological activities of toxins A and B of Clostridium difficile. Infect Immun. 1982 Mar;35(3):1147–1150. doi: 10.1128/iai.35.3.1147-1150.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Martinez R. D., Wilkins T. D. Comparison of Clostridium sordellii toxins HT and LT with toxins A and B of C. difficile. J Med Microbiol. 1992 Jan;36(1):30–36. doi: 10.1099/00222615-36-1-30. [DOI] [PubMed] [Google Scholar]
  20. McClead R. E., Jr, Butler T., Rabbani G. H. Orally administered bovine colostral anti-cholera toxin antibodies: results of two clinical trials. Am J Med. 1988 Dec;85(6):811–816. doi: 10.1016/s0002-9343(88)80026-3. [DOI] [PubMed] [Google Scholar]
  21. Mulligan M. E., Miller S. D., McFarland L. V., Fung H. C., Kwok R. Y. Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis. 1993 Jun;16 (Suppl 4):S239–S244. doi: 10.1093/clinids/16.supplement_4.s239. [DOI] [PubMed] [Google Scholar]
  22. Nord J., Ma P., DiJohn D., Tzipori S., Tacket C. O. Treatment with bovine hyperimmune colostrum of cryptosporidial diarrhea in AIDS patients. AIDS. 1990 Jun;4(6):581–584. doi: 10.1097/00002030-199006000-00015. [DOI] [PubMed] [Google Scholar]
  23. Pothoulakis C., Barone L. M., Ely R., Faris B., Clark M. E., Franzblau C., LaMont J. T. Purification and properties of Clostridium difficile cytotoxin B. J Biol Chem. 1986 Jan 25;261(3):1316–1321. [PubMed] [Google Scholar]
  24. Pothoulakis C., Kelly C. P., Joshi M. A., Gao N., O'Keane C. J., Castagliuolo I., Lamont J. T. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology. 1993 Apr;104(4):1108–1115. doi: 10.1016/0016-5085(93)90280-p. [DOI] [PubMed] [Google Scholar]
  25. Pothoulakis C., LaMont J. T., Eglow R., Gao N., Rubins J. B., Theoharides T. C., Dickey B. F. Characterization of rabbit ileal receptors for Clostridium difficile toxin A. Evidence for a receptor-coupled G protein. J Clin Invest. 1991 Jul;88(1):119–125. doi: 10.1172/JCI115267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Riegler M., Sedivy R., Pothoulakis C., Hamilton G., Zacherl J., Bischof G., Cosentini E., Feil W., Schiessel R., LaMont J. T. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest. 1995 May;95(5):2004–2011. doi: 10.1172/JCI117885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sullivan N. M., Pellett S., Wilkins T. D. Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun. 1982 Mar;35(3):1032–1040. doi: 10.1128/iai.35.3.1032-1040.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Tacket C. O., Binion S. B., Bostwick E., Losonsky G., Roy M. J., Edelman R. Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge. Am J Trop Med Hyg. 1992 Sep;47(3):276–283. doi: 10.4269/ajtmh.1992.47.276. [DOI] [PubMed] [Google Scholar]
  29. Tacket C. O., Losonsky G., Link H., Hoang Y., Guesry P., Hilpert H., Levine M. M. Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med. 1988 May 12;318(19):1240–1243. doi: 10.1056/NEJM198805123181904. [DOI] [PubMed] [Google Scholar]
  30. Tjellström B., Stenhammar L., Eriksson S., Magnusson K. E. Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis. Lancet. 1993 Mar 13;341(8846):701–702. doi: 10.1016/0140-6736(93)90477-x. [DOI] [PubMed] [Google Scholar]
  31. Triadafilopoulos G., Pothoulakis C., O'Brien M. J., LaMont J. T. Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology. 1987 Aug;93(2):273–279. doi: 10.1016/0016-5085(87)91014-6. [DOI] [PubMed] [Google Scholar]
  32. Viscidi R., Laughon B. E., Yolken R., Bo-Linn P., Moench T., Ryder R. W., Bartlett J. G. Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis. 1983 Jul;148(1):93–100. doi: 10.1093/infdis/148.1.93. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES